Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 11,745,000 | 11,047,000 | 6,779,000 | 10,783,000 | 13,085,000 |
| Cost of Goods | 3,342,000 | 2,991,000 | 1,101,000 | 2,874,000 | 3,751,000 |
| Gross Profit | 8,403,000 | 8,056,000 | 5,678,000 | 7,909,000 | 9,334,000 |
| Operating Expenses | 5,596,000 | 5,438,000 | 4,638,000 | 6,083,000 | 7,106,000 |
| Operating Income | 2,807,000 | 2,618,000 | 1,040,000 | 1,826,000 | 2,228,000 |
| Interest Expense | 216,000 | 200,000 | 191,000 | 206,000 | 202,000 |
| Other Income | 83,000 | 102,000 | 30,000 | -33,000 | 16,000 |
| Pre-tax Income | 2,674,000 | 2,520,000 | 879,000 | 1,587,000 | 2,042,000 |
| Income Tax | 403,000 | 370,000 | 74,000 | 257,000 | 347,000 |
| Net Income Continuous | 2,271,000 | 2,150,000 | 805,000 | 1,330,000 | 1,695,000 |
| Net Income Discontinuous | 46,000 | 144,000 | 661,000 | 245,000 | N/A |
| Minority Interests | 1,000 | 1,000 | N/A | 2,000 | 1,000 |
| Net Income | $2,316,000 | $2,293,000 | $1,466,000 | $1,573,000 | $1,694,000 |
| EPS Basic Total Ops | 1.11 | 1.09 | 0.69 | 0.73 | 0.77 |
| EPS Basic Continuous Ops | 1.09 | 1.02 | 0.39 | 0.61 | 0.77 |
| EPS Basic Discontinuous Ops | 0.02 | 0.07 | 0.30 | 0.11 | N/A |
| EPS Diluted Total Ops | 1.11 | 1.08 | 0.69 | 0.72 | 0.77 |
| EPS Diluted Continuous Ops | 1.08 | 1.01 | 0.38 | 0.61 | 0.77 |
| EPS Diluted Discontinuous Ops | 0.02 | 0.07 | 0.30 | 0.11 | N/A |
| EBITDA(a) | $2,807,000 | $4,534,000 | $2,834,000 | $3,591,000 | $4,127,000 |